Mark your calendars! The High Potent Medicines Conference is here

MarketsandMarkets, organizer of The High Potent Medicines Conference, is pleased to announce that Juergen Knoebel, Head – Small Molecules Quality Operations, F.Hoffmann La Roche AG, Switzerland has joined the speaker panel, to be held on 6th – 7th June 2017, in Berlin – Germany. Dr. Knoebel has held several leadership positions in the pharmaceutical and his experience includes a broad knowledge of the pharmaceutical industry for both Biotech and Small Molecules, including quality, compliance and regulatory aspects covering quality management, quality systems, and medical and regulatory affairs in the GxP environment. The conference is a platform that will gather key experts and researchers from contract manufacturing organizations (CMOs) and pharma/bio – pharma organizations to address current market trends, technological advancements and future challenges in manufacture and development of HPAPI compounds.

Recently, in a short pre-event interview with MarketsandMarkets, Dr. Knoebel, talked about the recent advances in the high potent medicines area and current challenges that need immediate attention. He highlighted a few areas where advancements in the manufacturing process have been instrumental in ensuring safety and efficient production. He stated, “Through new approaches for manufacturing high potent compounds, we have achieved a sound knowledge of scientifically acceptable levels of carry-over from one product to another. We now have the opportunity to apply modern containment concepts and better manufacturing controls to assure safe products while at the same time being cost effective in production.”

Dr. Juergen Knoebel will share his views on ‘Handling of highly potent products in a multi-product facility’ with a focus on understanding cross-contamination control procedures, ADE Concept and multi-product facility risk management. Joining him on the speaker panel will be global experts representing companies such as Novartis, Bristol-Myers Squibb, Hovione, Boehringer Ingelheim, Oril Industrie-Servier, AstraZeneca and Leeds Beckett University.

The conference will consist of presentations, panel discussions and case studies on topics on HPAPI manufacturing process – addressing the concept, technology and challenges like process validation considerations and scale-up in high potent API production, strategies for effective management of HPAPI supply chain, overcoming regulatory challenges for ADC’s, validation of cleaning procedures to avoid cross contamination, containment and safety of pharmaceutical toxic powders, managing cleaning validation in biologics, risk identification and mitigation for high potent compounds and strategies to integrate PAT in the QbD process.

The two – day meet will be a great opportunity to network, share expertise and stay updated with the latest practices in manufacturing of high potent medicines. The conference is supported by BIO Deutschland, European Biotechnology Network (EBN), ASEBIO – Spanish Bioindustry Association and the Swiss Biotech Association (SBA).